Abzena, a prominent integrated CDMO specializing in complex biologics, has granted Orion an exclusive commercial license for a monoclonal antibody (mAb) aimed at treating a cancer with significant clinical unmet need. This strategic partnership is set to enhance Orion’s oncology-focused drug research and development (R&D) pipeline, positioning the company to address critical gaps in cancer treatment.
The mAb, developed at Abzena’s Cambridge facility, utilizes their proprietary Composite Human Antibody (CHAb™) technology. This innovative approach integrates a comprehensive developability platform, enabling the selection of a lead candidate that minimizes risks associated with downstream development and clinical efficacy. The antibody’s manufacturing process benefits from Abzena’s AbZelectPRO™ cell line development platform, ensuring a stable and productive production process.
According to Campbell Bunce, Chief Scientific Officer of Abzena, the collaboration with Orion has yielded a de-risked lead antibody that enhances the likelihood of success in clinical settings. Antti Haapalinna, Vice President at Orion, echoed this sentiment, highlighting the effective partnership and its outcomes. With over two decades of experience, Abzena is well-equipped to support antibody programs, offering comprehensive services from discovery through to commercial launch, thereby facilitating faster advancement of novel therapies.
Use the database as your supply chain compass →
